title: Retention of Endogenous Viable Cells Enhances the Anti-Inflammatory Activity of Cryopreserved Amnion.
abstract: Objective:Human amniotic membrane (hAM) has been used to treat wounds for more than 100 years. However, widespread use of fresh hAM has been limited due to its short shelf life and safety concerns. To overcome these concerns, different preservation methods have been introduced. The majority of these methods result in devitalized hAM (dev-hAM). Recently, we developed a cryopreservation method that retains all hAM components intact (int-hAM), including viable endogenous cells. To understand the advantages of retaining viable cells in preserved hAM, we compared the anti-inflammatory properties of int-hAM and dev-hAM.Approach:The tissue composition of int-hAM and dev-hAM was compared with fresh hAM through histology and cell viability analysis. We also evaluated the ability of int-hAM and dev-hAM to regulate tumor necrosis factor-α (TNF-α), interleukin-1α (IL-1α), and IL-10 release when co-cultured with immune cells; to produce prostaglandin E2 (PGE2) on TNF-α stimulation; and to inhibit proteases.Results:Int-hAM maintained the structural and cellular integrity of fresh hAM. Int-hAM had >80% cell viability post-thaw and remained viable for at least a week in culture. Viable cells were not detected in dev-hAM. Compared with dev-hAM, int-hAM showed significantly greater downregulation of TNF-α and IL-1α, upregulation of PGE2 and IL-10, and stronger inhibition of collagenase.Innovation and Conclusion:A new cryopreservation method has been developed to retain all native components of hAM. For the first time, we show that viable endogenous cells significantly augment the anti-inflammatory activity of cryopreserved hAM.
authors.affiliation: Osiris Therapeutics, Inc., Columbia, Maryland.
authors.forename: Yi
authors.initials: Y
authors.lastname: Duan-Arnold
authors.affiliation: Osiris Therapeutics, Inc., Columbia, Maryland.
authors.forename: Alexandra
authors.initials: A
authors.lastname: Gyurdieva
authors.affiliation: Osiris Therapeutics, Inc., Columbia, Maryland.
authors.forename: Amy
authors.initials: A
authors.lastname: Johnson
authors.affiliation: Osiris Therapeutics, Inc., Columbia, Maryland.
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Uveges
authors.affiliation: Osiris Therapeutics, Inc., Columbia, Maryland. ; ThermoFisher Scientific, Inc., Portage, Michigan.
authors.forename: Douglas A
authors.initials: DA
authors.lastname: Jacobstein
authors.affiliation: Osiris Therapeutics, Inc., Columbia, Maryland.
authors.forename: Alla
authors.initials: A
authors.lastname: Danilkovitch